Collaborating closely with disease experts from non- profit and academic institutions around the globe, CGH has utilized the diverse, drug-like properties of the company’s library of more than 400,000 compounds to fuel the CGH pipeline.
CGH has a pipeline with more than ten discovery stage programs and phase II clinical trials in eleven indications/diseases areas that are ongoing or planned. It is the goal of CGH to not only bring novel therapies to patients in need, but also, to continue to develop a full pipeline for target diseases — just as Celgene does throughout its R&D.
NTD RESEARCH AND DEVELOPMENT WITH DRUGS FOR NEGLECTED DISEASES initiative (DNDi)
DNDi, a non-profit drug research and development (R&D) organization, develops new treatments for neglected diseases. The CGH-DNDi collaboration was initiated in 2011 with the screening of the CGH-DNDi compound library for activity against NTDs. Over the last few years, the collaboration has evolved to include the identification and optimization of potential therapeutic candidates for several of the world’s most neglected tropical diseases such as, leishmaniasis (VL and CL), Chagas disease, and filarial diseases. Current efforts include continued screening of novel chemical matter from the CGH compound library.
MALARIA RESEARCH AND DEVELOPMENT WITH MEDICINES FOR MALARIA VENTURE (MMV)
In collaboration with MMV, the leading product development partnership in the field of antimalarial R & D, we have created several novel classes of anti-malarial compounds from hits identified in phenotypic screens against Plasmodium falciparum (blood stage parasite) and Plasmodium vivax (liver stage parasite). These compounds are being optimized for potency, properties, and selectivity.
DNDI DRUG DISCOVERY BOOSTER CONSORTIUM
In 2016, CGH joined the Neglected Tropical Diseases Drug Discovery Booster consortium, a new venture of the Drugs for Neglected Diseases initiative (DNDi), designed to accelerate and reduce the cost of early stage drug discovery for two of the world’s most neglected diseases: leishmaniasis and Chagas disease.
Our other global partners and projects include:
- H3-D, Drug Discovery and Development Center at the University of Cap Town in South Africa: identifying and developing next generation therapies for patients with tuberculosis and malaria
- PATH, leader in global health innovation, accelerating innovation across five platforms — vaccines, drugs, diagnostics, devices, and system and service innovations: identifying novel therapies for cryptosporidiosis
- Bill and Melinda Gates foundation (BMGF), working globally to reduce inequality: partnering to identify novel medicines for TB and filarial disease